Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

BACKGROUND: E75 (nelipepimut-S) is a human leukocyte antigen (HLA)-A2/A3-restricted immunogenic peptide derived from the HER2 protein. We have conducted phase I/II clinical trials vaccinating breast cancer patients with nelipepimut-S and granulocyte–macrophage colony-stimulating factor (GM-CSF) in t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mittendorf, E. A., Clifton, G. T., Holmes, J. P., Schneble, E., van Echo, D., Ponniah, S., Peoples, G. E.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4143091/
https://ncbi.nlm.nih.gov/pubmed/24907636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu211
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados